期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 26, 期 4, 页码 592-598出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2007.11.5378
关键词
-
类别
Purpose The Breast Cancer-Anemia and the Value of Erythropoietin ( BRAVE) study evaluated whether epoetin beta would improve survival in patients with metastatic breast cancer ( MBC). Patients and Methods BRAVE was an open-label, randomized, multicenter study in patients with MBC treated with anthracycline- and/or taxane-based chemotherapy. Patients ( hemoglobin [ Hb] < 12.9 g/dL) were randomly assigned ( 1: 1) to epoetin beta 30,000 U subcutaneously once weekly or control for 24 weeks. The primary efficacy variable was overall survival. Secondary efficacy outcomes included progression-free survival, transfusion- and severe anemia-free survival, Hb response, safety, and quality of life ( QoL). Results After 18 months of follow-up, 62 ( 27%) of 231 patients survived with epoetin beta therapy and 63 ( 27%) of 232 with control. No difference was detected in overall survival ( hazard ratio [ HR] = 1.07; 95% CI, 0.87 to 1.33, P =.522) or progression-free survival ( HR = 1.07; 95% CI, 0.89 to 1.30, P =.448). There was a statistically significant benefit on transfusion- and severe anemia-free survival compared with control ( HR = 0.59; P =.0097). Median Hb level increased with epoetin beta ( 11.7 g/dL at baseline to 13.3 g/dL at 24 weeks) but did not change with control ( 11.5 v 11.4 g/dL). Patients receiving epoetin beta experienced more thromboembolic events ( TEEs) compared with controls ( 13% v 6%; P =.012) with no difference in serious TEEs ( 4% v 3%). Epoetin beta did not significantly improve QoL in this study where patients had a high baseline Hb value. Conclusion In patients with MBC receiving chemotherapy and initial Hb less than 12.9 g/dL, epoetin beta increased Hb. No difference was detected in overall survival. Because of its superiority design, this study cannot, however, exclude clinically important differences in survival with absolute certainty.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据